Bayesian Estimation of Pharmacokinetic and Pharmacodynamic Parameters in a Mode‐of‐Action‐Based Cancer Risk Assessment for Chloroform

Chloroform is a carcinogen in rodents and its carcinogenicity is secondary to events associated with cytotoxicity and regenerative cell proliferation. In this study, a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model that links the processes of chloroform metabolism, reparable cell damage, cell death, and regenerative cellular proliferation was developed to support a new cancer dose-response assessment for chloroform. Model parameters were estimated using Markov Chain Monte Carlo (MCMC) analysis in a two-step approach: (1) metabolism parameters for male and female mice and rats were estimated against available closed chamber gas uptake data; and (2) PD parameters for each of the four rodent groups were estimated from hepatic and renal labeling index data following inhalation exposures. Subsequently, the resulting rodent PD parameters together with literature values for human age-dependent physiological and metabolism parameters were used to scale up the rodent model to a human model. The human model was used to predict exposure conditions under which chloroform-mediated cytolethality is expected to occur in liver and kidney of adults and children. Using the human model, inhalation Reference Concentrations (RfCs) and oral Reference Doses (RfDs) were derived using an uncertainty factor of 10. Based on liver and kidney dose metrics, the respective RfCs were 0.9 and 0.09 ppm; and the respective RfDs were 0.4 and 3 mg/kg/day.

[1]  Harvey J Clewell,et al.  Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations. , 2006, Regulatory toxicology and pharmacology : RTP.

[2]  Fredrik U. Jönsson,et al.  Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. , 2001, Toxicology.

[3]  J. Laskey,et al.  The Metabolic Rate Constants and Specific Activity of Human and Rat Hepatic Cytochrome P-450 2E1 Toward Toluene and Chloroform , 2004, Journal of toxicology and environmental health. Part A.

[4]  Brian A. Wong,et al.  A 90-day chloroform inhalation study in F-344 rats: profile of toxicity and relevance to cancer studies. , 1996, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[5]  M. Rubin,et al.  Maturation of renal function in childhood; clearance studies. , 1949, The Journal of clinical investigation.

[6]  I. Ijiri,et al.  A statistical analysis of the internal organ weights of normal Japanese people. , 1997, Health physics.

[7]  Bradley P. Carlin,et al.  BAYES AND EMPIRICAL BAYES METHODS FOR DATA ANALYSIS , 1996, Stat. Comput..

[8]  Harvey J Clewell,et al.  Evaluation of Physiologically Based Pharmacokinetic Models in Risk Assessment: An Example with Perchloroethylene , 2005, Critical reviews in toxicology.

[9]  G. Johanson,et al.  Physiologically based modeling of the inhalation kinetics of styrene in humans using a bayesian population approach. , 2002, Toxicology and applied pharmacology.

[10]  Yu-Mei Tan,et al.  Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[11]  G. Johanson,et al.  A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. , 2001, Toxicology and applied pharmacology.

[12]  W. K. Hastings,et al.  Monte Carlo Sampling Methods Using Markov Chains and Their Applications , 1970 .

[13]  A. Gelman,et al.  Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .

[14]  Harvey J Clewell,et al.  Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice. , 2006, Regulatory toxicology and pharmacology : RTP.

[15]  Brian J. Smith,et al.  BAYESIAN OUTPUT ANALYSIS PROGRAM (BOA) VERSION 1.1 USER'S MANUAL , 2003 .

[16]  Frédéric Y. Bois,et al.  Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects , 2001, Archives of Toxicology.

[17]  F. Guengerich,et al.  Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. , 1991, Chemical research in toxicology.

[18]  Tammie R. Covington,et al.  Evaluation of the Potential Impact of Age- and Gender-Specific Lung Morphology and Ventilation Rate on the Dosimetry of Vapors , 2003, Inhalation toxicology.

[19]  C. Wolf,et al.  Evidence that the androgen receptor mediates sexual differentiation of mouse renal cytochrome P450 expression. , 1991, The Biochemical journal.

[20]  M E Andersen,et al.  Development of a physiologically based pharmacokinetic model for chloroform. , 1990, Toxicology and applied pharmacology.

[21]  F Y Bois,et al.  Statistical issues in toxicokinetic modeling: a bayesian perspective. , 2000, Environmental health perspectives.

[22]  H J Clewell,et al.  Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. , 2001, The Science of the total environment.

[23]  Harvey J Clewell,et al.  Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. , 2002, Regulatory toxicology and pharmacology : RTP.

[24]  D. Wolf,et al.  Patterns of chloroform-induced regenerative cell proliferation in BDF1 mice correlate with organ specificity and dose-response of tumor formation. , 1998, Carcinogenesis.

[25]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[26]  J. Gearhart,et al.  In vivo metabolism of chloroform in B6C3F1 mice determined by the method of gas uptake: the effects of body temperature on tissue partition coefficients and metabolism. , 1993, Toxicology and applied pharmacology.

[27]  F Y Bois,et al.  Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics. , 2000, Environmental health perspectives.

[28]  Sylvia Richardson,et al.  Inference and monitoring convergence , 1995 .

[29]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[30]  N. Metropolis,et al.  Equation of State Calculations by Fast Computing Machines , 1953, Resonance.

[31]  Andrew Gelman,et al.  General methods for monitoring convergence of iterative simulations , 1998 .

[32]  D. Wolf,et al.  Acute hepatotoxic and nephrotoxic effects of chloroform in male F-344 rats and female B6C3F1 mice , 1993 .

[33]  Melvin E. Andersen,et al.  Applying Mode-of-Action and Pharmacokinetic Considerations in Contemporary Cancer Risk Assessments: An Example with Trichloroethylene , 2004 .

[34]  F Y Bois,et al.  Analysis of PBPK Models for Risk Characterization , 1999, Annals of the New York Academy of Sciences.

[35]  C. Wolf,et al.  Testosterone-mediated regulation of mouse renal cytochrome P-450 isoenzymes. , 1990, The Biochemical journal.

[36]  H. Arito,et al.  Carcinogenicity and Chronic Toxicity in Rats and Mice Exposed to Chloroform by Inhalation , 2002 .

[37]  Don R. Maszle,et al.  MCSim: A Monte Carlo Simulation Program , 1997 .